These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19. Yang Y; Lewis JP; Hulot JS; Scott SA Expert Opin Drug Metab Toxicol; 2015; 11(10):1599-617. PubMed ID: 26173871 [TBL] [Abstract][Full Text] [Related]
25. Will personalized drugs for cardiovascular disease become an option? - Defining 'Evidence-based personalized medicine' for its implementation and future use. de Denus S; Dubé MP; Tardif JC Expert Opin Pharmacother; 2015; 16(17):2549-52. PubMed ID: 26371722 [TBL] [Abstract][Full Text] [Related]
26. Clinical pharmacogenomics: patient perspectives of pharmacogenomic testing and the incidence of actionable test results in a chronic disease cohort. Mukherjee C; Sweet KM; Luzum JA; Abdel-Rasoul M; Christman MF; Kitzmiller JP Per Med; 2017 Sep; 14(5):383-388. PubMed ID: 29181084 [TBL] [Abstract][Full Text] [Related]
27. The Daniel K. Inouye College of Pharmacy Scripts: Precision Medicine Through the Use of Pharmacogenomics: Current Status and Barriers to Implementation. Ciarleglio AE; Ma C Hawaii J Med Public Health; 2017 Sep; 76(9):265-269. PubMed ID: 28900583 [TBL] [Abstract][Full Text] [Related]
29. Evidence-based pharmacogenetics: Is it possible? Sychev DA; Malova EU Int J Risk Saf Med; 2015; 27 Suppl 1():S97-8. PubMed ID: 26639733 [TBL] [Abstract][Full Text] [Related]
30. Pharmacogenomic Challenges in Cardiovascular Diseases: Examples of Drugs and Considerations for Future Integration in Clinical Practice. Chatelin J; Stathopoulou MG; Arguinano AA; Xie T; Visvikis-Siest S Curr Pharm Biotechnol; 2017; 18(3):231-241. PubMed ID: 28117005 [TBL] [Abstract][Full Text] [Related]
31. Cases in Precision Medicine: The Role of Pharmacogenetics in Precision Prescribing. Lin B; Chung WK Ann Intern Med; 2019 Jun; 170(11):796-804. PubMed ID: 31108507 [TBL] [Abstract][Full Text] [Related]
32. CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta-analysis of randomized clinical trials. Kheiri B; Osman M; Abdalla A; Haykal T; Pandrangi PV; Chahine A; Ahmed S; Osman K; Bachuwa G; Hassan M; Bhatt DL Catheter Cardiovasc Interv; 2019 Jun; 93(7):1246-1252. PubMed ID: 30403317 [TBL] [Abstract][Full Text] [Related]
35. Clinical Implementation of Pharmacogenomics for Personalized Precision Medicine: Barriers and Solutions. Klein ME; Parvez MM; Shin JG J Pharm Sci; 2017 Sep; 106(9):2368-2379. PubMed ID: 28619604 [TBL] [Abstract][Full Text] [Related]
36. Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran. Ross S; Paré G Pharmacogenomics; 2013 Oct; 14(13):1565-72. PubMed ID: 24088127 [TBL] [Abstract][Full Text] [Related]
37. Pharmacogenetics-Based versus Conventional Dosing of Warfarin: A Meta-Analysis of Randomized Controlled Trials. Shi C; Yan W; Wang G; Wang F; Li Q; Lin N PLoS One; 2015; 10(12):e0144511. PubMed ID: 26672604 [TBL] [Abstract][Full Text] [Related]